CDC7

Summary

CDC7 (cell division cycle 7, HGNC:1745) is a protein-coding gene on chromosome 1p22.1, encoding Cell division cycle 7-related protein kinase (O00311). Kinase involved in initiation of DNA replication. It is a common-essential gene (DepMap: required in 99.9% of cancer cell lines).

This gene encodes a cell division cycle protein with kinase activity that is critical for the G1/S transition. The yeast homolog is also essential for initiation of DNA replication as cell division occurs. Overexpression of this gene product may be associated with neoplastic transformation for some tumors. Multiple alternatively spliced transcript variants that encode the same protein have been detected.

Source: NCBI Gene 8317 — RefSeq curated summary.

At a glance

• GWAS associations: 24
• Clinical variants (ClinVar): 97 total
• Druggable target: yes — 7 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_003503

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1745
Approved symbol	CDC7
Name	cell division cycle 7
Location	1p22.1
Locus type	gene with protein product
Status	Approved
Aliases	Hsk1, huCdc7, HsCdc7
Ensembl gene	ENSG00000097046
Ensembl biotype	protein_coding
OMIM	603311
Entrez	8317

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 19 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000234626, ENST00000426137, ENST00000428239, ENST00000486509, ENST00000497611, ENST00000897932, ENST00000897933, ENST00000897934, ENST00000897935, ENST00000897936, ENST00000897937, ENST00000913029, ENST00000913030, ENST00000913031, ENST00000913032, ENST00000913033, ENST00000913034, ENST00000913035, ENST00000913036, ENST00000913037, ENST00000913038

RefSeq mRNA: 3 — MANE Select: NM_003503 NM_001134419, NM_001134420, NM_003503

CCDS: CCDS734

Canonical transcript exons

ENST00000234626 — 12 exons

Exon	Start	End
ENSE00000776455	91520130	91520279
ENSE00001296115	91524041	91525764
ENSE00001647687	91511781	91511923
ENSE00001670120	91513948	91514043
ENSE00001697785	91513058	91513307
ENSE00001773076	91511597	91511690
ENSE00001800055	91508262	91508397
ENSE00001918304	91500851	91500948
ENSE00003483533	91501654	91501831
ENSE00003483775	91507854	91507937
ENSE00003518422	91515794	91515876
ENSE00003587648	91514819	91514997

Expression profiles

Bgee: expression breadth ubiquitous, 218 present calls, max score 98.01.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.5353 / max 380.6294, expressed in 1554 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
4008	11.5161	1421
4009	2.0396	861
4007	0.6463	344
4010	0.2620	120
4011	0.0713	26

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.01	gold quality
oocyte	CL:0000023	95.55	gold quality
endothelial cell	CL:0000115	93.45	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.92	gold quality
ventricular zone	UBERON:0003053	87.73	gold quality
embryo	UBERON:0000922	86.82	gold quality
ganglionic eminence	UBERON:0004023	86.05	gold quality
buccal mucosa cell	CL:0002336	86.02	gold quality
cortical plate	UBERON:0005343	86.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.63	gold quality
cerebellar hemisphere	UBERON:0002245	83.61	gold quality
cerebellar cortex	UBERON:0002129	83.54	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.39	gold quality
cerebellum	UBERON:0002037	82.28	gold quality
testis	UBERON:0000473	81.72	gold quality
right testis	UBERON:0004534	81.16	gold quality
left testis	UBERON:0004533	81.04	gold quality
spleen	UBERON:0002106	79.71	gold quality
bone marrow	UBERON:0002371	79.40	gold quality
primary visual cortex	UBERON:0002436	77.75	gold quality
adrenal tissue	UBERON:0018303	77.39	gold quality
lymph node	UBERON:0000029	76.91	gold quality
Brodmann (1909) area 23	UBERON:0013554	76.73	gold quality
trabecular bone tissue	UBERON:0002483	76.37	gold quality
vermiform appendix	UBERON:0001154	76.23	gold quality
prefrontal cortex	UBERON:0000451	76.18	gold quality
rectum	UBERON:0001052	76.16	gold quality
middle temporal gyrus	UBERON:0002771	76.04	gold quality
right frontal lobe	UBERON:0002810	75.78	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	75.76	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.47
E-GEOD-99795	no	139.78

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI2, STAT1

miRNA regulators (miRDB)

73 targeting CDC7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-548M	99.70	68.87	1749

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• Drf1, a nuclear cell cycle-regulated protein binds to Cdc7 and activates the kinase (PMID:12065429)
• Down-regulation of Cdc7 by small interfering RNA in a variety of tumor cell lines causes an abortive S phase, leading to cell death by either p53-independent apoptosis or aberrant mitosis. (PMID:15466207)
• CR (periphilin) retards S-phase progression by modifying expression of Cdc7 and other genes involved in progression of DNA replication (PMID:15474462)
• ASKL1 in a complex with Cdc7 may play a role in normal progression of both S and M phases (PMID:15668232)
• CINP is part of the Cdc7-dependent mechanism of origin firing and a functional and physical link between Cdk2 and Cdc7 complexes at the origins (PMID:16082200)
• the majority of the Mcm2 isoforms phosphorylated by Cdc7 are not stably associated with chromatin (PMID:16446360)
• Cdc7-Dbf4 kinase efficiently phosphorylates p150. (PMID:16826239)
• Results describe the mapping of the sites in human Mcm2 protein that are phosphorylated by Cdc7. (PMID:16864800)
• Taken together, these results indicate that Cdc7/Dbf4 phosphorylation of MCM2 is essential for the initiation of DNA replication in mammalian cells. (PMID:16899510)
• MCM4 phosphorylation by Cdc7 kinase facilitates its interaction with Cdc45 on chromatin (PMID:17046832)
• Cdc7 kinase plays a role in maintaining cell viability during replication stress (PMID:17062569)
• CRM1 may down-regulate Cdc7 by masking its kinase domain (PMID:17711849)
• Cdc7/Dbf4 kinase activity inhibition affects specific phosphorylation sites on MCM2 in cancer cells (PMID:18286467)
• the ATR-dependent activation of the p38 MAP kinase is a major signaling pathway that induces apoptotic cell death after depletion of Cdc7 in cancer cells (PMID:18625709)
• increased Cdc7-Dbf4 abundance may be a common occurrence in human malignancies (PMID:18714392)
• chromatin-bound CDT1 is first stabilized and subsequently displaced by CDC7 activity, thereby ensuring the timely execution of DNA replication (PMID:19054765)
• These results indicate that Ddk functions as an upstream regulator to monitor S-phase checkpoint signaling. (PMID:19111665)
• differences in Cdc7 expression may account for some of the differences between malignant melanomas and benign melanocytic nevi. (PMID:19278428)
• Increased Cdc7 protein levels were significantly associated with arrested tumor differentiation, advanced clinical stage, genomic instability, and accelerated cell cycle progression. (PMID:19318489)
• Data show that CDC7L1 and CDC10 was up-regulated but the expression of CDK9, CDC20 and CLK3 was down- regulated in azoospermic testes. (PMID:19426592)
• Cdc7 phosphorylates Mcm2 promoting pre-replication complex assembly. (PMID:19647517)
• The interaction with LEDGF relieves autoinhibition of Cdc7-ASK kinase, imposed by the C terminus of ASK. (PMID:19864417)
• cell division cycle 7 is a replication associated protein with relationships to gene amplification and genomic instability in breast carcinomas. (PMID:19896697)
• Inhibition of Cdc7 kinase activity in cancer cells restricts DNA replication and induces apoptotic cell death by an unprecedented molecular mechanism of action. (PMID:20647475)
• Data syggest important implications for the continued development of promising Cdc7-targeted cancer therapies. (PMID:20707412)
• bipartite interaction between Cdc7 and Dbf4/ASK subunits facilitates ATP binding and substrate recognition by the Cdc7 kinase. (PMID:21536671)
• The results suggest that CDC7 expression level can be specific prognostic factors for Diffuse large B-cell lymphoma patients (PMID:22528513)
• cell death process induced by Cdc7 depletion (PMID:22574151)
• Significantly higher levels of apoptosis were detected in siCDC7-transfected cells. (PMID:22806309)
• Cdc7 phosphorylates and interacts with Tob to inhibit the Cul4-DDB1(Cdt2)-dependent Tob degradation. (PMID:23066029)
• The interaction between Claspin and Cdc7 is not dependent on Cdc7 kinase activity, but Claspin interaction with the DNA helicase subunit Mcm2 is lost upon Cdc7 inhibition. (PMID:23598722)
• Cdcy is universally up-regulated in oral squamous cell carcinoma is an independent prognostic marker, contributing to resistance to DNA damaging agents. (PMID:23684929)
• huCdc7 may play an important role in the development and progression of colorectal cancer. (PMID:23716994)
• MiR-630 promoted apoptosis by downregulation of CDC7. (PMID:25255219)
• The state of DUE-B phosphorylation is maintained by the equilibrium between Cdc7-dependent phosphorylation and PP2A-dependent dephosphorylation. (PMID:25258324)
• Our data show that Cdc7 is highly expressed in colorectal cancer (PMID:26208856)
• The presence of the index SNP rs1192415 (TGFBR3-CDC7) was associated with visual field progression in POAG (primary open-angle glaucoma) patients. (PMID:26383992)
• The data support a model where Cdc7 (de)phosphorylation is the molecular switch for the activation and inactivation of DNA replication in mitosis, directly connecting Cdc7 and PP1a/Cdk1 to the regulation of once-per-cell cycle DNA replication in mammalian cells. (PMID:27105124)
• Results suggest a new role of Claspin in initiation of DNA replication during normal S phase through the recruitment of Cdc7 that facilitates phosphorylation of Mcm proteins. (PMID:27401717)
• we propose that phosphorylation of TOP2A by CDC7/DBF4 in early S-phase prevents its localization and/or activity at centromeres, and inhibition of TOP2A function could be relevant to prevent premature separation of centromeric DNA. (PMID:27407105)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdc7	ENSDARG00000023584
mus_musculus	Cdc7	ENSMUSG00000029283
rattus_norvegicus	Cdc7	ENSRNOG00000002105
drosophila_melanogaster	Cdc7	FBGN0028360
drosophila_melanogaster	CG5790	FBGN0032677
caenorhabditis_elegans	cdc-7	WBGENE00016421

Paralogs (12): VRK2 (ENSG00000028116), VRK1 (ENSG00000100749), VRK3 (ENSG00000105053), CSNK1A1 (ENSG00000113712), TTBK2 (ENSG00000128881), CSNK1G2 (ENSG00000133275), CSNK1D (ENSG00000141551), TTBK1 (ENSG00000146216), CSNK1G3 (ENSG00000151292), CSNK1G1 (ENSG00000169118), CSNK1A1L (ENSG00000180138), CSNK1E (ENSG00000213923)

Protein

Protein identifiers

Cell division cycle 7-related protein kinase — O00311 (reviewed: O00311)

All UniProt accessions (3): O00311, A0A384MTU6, B1AMW7

UniProt curated annotations — full annotation on UniProt →

Function. Kinase involved in initiation of DNA replication. Phosphorylates critical substrates that regulate the G1/S phase transition and initiation of DNA replication, such as MCM proteins and CLASPIN.

Subunit / interactions. Forms a complex with either DBF4/DBF4A or DBF4B, leading to the activation of the kinase activity. Interacts with CLASPIN (via the acidic patch); the interaction is required for phosphorylation of MCM proteins and CLASPIN.

Subcellular location. Nucleus.

Similarity. Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. CDC7 subfamily.

Isoforms (1)

UniProt ID	Names	Canonical?
O00311-1	1	yes

RefSeq proteins (3): NP_001127891, NP_001127892, NP_003494* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (51 total): helix 18, strand 11, sequence variant 9, turn 4, binding site 2, modified residue 2, chain 1, domain 1, sequence conflict 1, active site 1, cross-link 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
6YA6	X-RAY DIFFRACTION	1.44
6YA7	X-RAY DIFFRACTION	1.67
6YA8	X-RAY DIFFRACTION	1.79
4F9C	X-RAY DIFFRACTION	2.08
4F9A	X-RAY DIFFRACTION	2.17
5UWR	X-RAY DIFFRACTION	2.24
5UWQ	X-RAY DIFFRACTION	2.28
4F99	X-RAY DIFFRACTION	2.33
4F9B	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00311-F1	72.49	0.57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 177 (proton acceptor)

Ligand- & substrate-binding residues (2): 64–72; 90

Post-translational modifications (3): 27, 503, 268

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-176187	Activation of ATR in response to replication stress
R-HSA-68962	Activation of the pre-replicative complex
R-HSA-8953750	Transcriptional Regulation by E2F6
R-HSA-1640170	Cell Cycle
R-HSA-212436	Generic Transcription Pathway
R-HSA-453279	Mitotic G1 phase and G1/S transition
R-HSA-69002	DNA Replication Pre-Initiation
R-HSA-69206	G1/S Transition
R-HSA-69278	Cell Cycle, Mitotic
R-HSA-69306	DNA Replication
R-HSA-69481	G2/M Checkpoints
R-HSA-69620	Cell Cycle Checkpoints
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 308 (showing top): REACTOME_DNA_REPLICATION, GOBP_POSITIVE_REGULATION_OF_DNA_REPLICATION, WALLACE_PROSTATE_CANCER_RACE_UP, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, TGCGCANK_UNKNOWN, GOBP_REGULATION_OF_DNA_TEMPLATED_DNA_REPLICATION, GOBP_CELL_CYCLE_DNA_REPLICATION, FISCHER_G1_S_CELL_CYCLE, GOBP_CELL_CYCLE_PHASE_TRANSITION, GEORGES_CELL_CYCLE_MIR192_TARGETS, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS, MITSIADES_RESPONSE_TO_APLIDIN_DN, KONG_E2F3_TARGETS

GO Biological Process (9): G1/S transition of mitotic cell cycle (GO:0000082), double-strand break repair via break-induced replication (GO:0000727), signal transduction (GO:0007165), positive regulation of cell population proliferation (GO:0008284), positive regulation of nuclear cell cycle DNA replication (GO:0010571), positive regulation of G2/M transition of mitotic cell cycle (GO:0010971), cell cycle phase transition (GO:0044770), cell division (GO:0051301), protein phosphorylation (GO:0006468)

GO Molecular Function (9): protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), kinase activity (GO:0016301), metal ion binding (GO:0046872), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), intercellular bridge (GO:0045171), mitotic spindle (GO:0072686)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
Cell Cycle	2
G2/M Checkpoints	1
DNA Replication Pre-Initiation	1
G1/S Transition	1
Generic Transcription Pathway	1
RNA Polymerase II Transcription	1
Cell Cycle, Mitotic	1
DNA Replication	1
Mitotic G1 phase and G1/S transition	1
Cell Cycle Checkpoints	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cellular process	2
protein kinase activity	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
double-strand break repair via homologous recombination	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
nuclear DNA replication	1
regulation of nuclear cell cycle DNA replication	1
positive regulation of cell cycle process	1
positive regulation of DNA-templated DNA replication	1
G2/M transition of mitotic cell cycle	1
regulation of G2/M transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
positive regulation of cell cycle G2/M phase transition	1
cell cycle process	1
phosphorylation	1
protein modification process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
transferase activity, transferring phosphorus-containing groups	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
spindle	1

Protein interactions and networks

STRING

2634 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDC7	DBF4	Q9UBU7	999
CDC7	CDC45	O75419	970
CDC7	MCM4	P33991	968
CDC7	CDC6	Q99741	943
CDC7	MCM3	P25205	928
CDC7	TICRR	Q7Z2Z1	916
CDC7	MCM5	P33992	904
CDC7	DBF4B	Q8NFT6	901
CDC7	CDT1	Q9H211	880
CDC7	MCM10	Q7L590	834
CDC7	TOPBP1	Q92547	828
CDC7	CDC14A	Q9UNH5	824
CDC7	MCM6	Q14566	822
CDC7	MCM7	P33993	821
CDC7	CHEK2	O96017	805

IntAct

134 interactions, top by confidence:

A	B	Type	Score
DBF4	CDC7	psi-mi:“MI:0914”(association)	0.890
DBF4	CDC7	psi-mi:“MI:0915”(physical association)	0.890
CDC7	DBF4	psi-mi:“MI:0915”(physical association)	0.890
DBF4	CDC7	psi-mi:“MI:0915”(physical association)	0.610
DBF4	CDC7	psi-mi:“MI:0407”(direct interaction)	0.610
CDC7	MCMBP	psi-mi:“MI:0915”(physical association)	0.590
CDC7	IKZF1	psi-mi:“MI:0915”(physical association)	0.560
	CDC7	psi-mi:“MI:0915”(physical association)	0.560
CDC7	ZBTB8B	psi-mi:“MI:0915”(physical association)	0.560
CDC7	TSNAXIP1	psi-mi:“MI:0915”(physical association)	0.560
CDC7	IKZF4	psi-mi:“MI:0915”(physical association)	0.560
CDC7	FXR1	psi-mi:“MI:0915”(physical association)	0.560
CDC7	BANP	psi-mi:“MI:0915”(physical association)	0.560
CDC7	TRIM37	psi-mi:“MI:0915”(physical association)	0.560
CDC7	IKZF3	psi-mi:“MI:0915”(physical association)	0.560
CDC7	ZBTB10	psi-mi:“MI:0915”(physical association)	0.560
CDC7	CALCOCO2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	ZBTB26	psi-mi:“MI:0915”(physical association)	0.560
CDC7	TRIM27	psi-mi:“MI:0915”(physical association)	0.560
CDC7	GOLGA2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	SERTAD2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	STAM2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	GMEB2	psi-mi:“MI:0915”(physical association)	0.560
CDC7	LZTS1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (195): CDC7 (Affinity Capture-MS), CDC7 (Co-fractionation), CDC7 (Proximity Label-MS), CDC7 (Affinity Capture-MS), CDC7 (Affinity Capture-MS), CDC7 (Affinity Capture-MS), CDC7 (Affinity Capture-MS), IFT122 (Affinity Capture-MS), BRD4 (Synthetic Lethality), RPS11 (Synthetic Lethality), ING5 (Synthetic Lethality), CDC7 (Two-hybrid), CDC7 (Affinity Capture-MS), CDC7 (Affinity Capture-MS), CDC7 (Affinity Capture-MS)

ESM2 similar proteins: A2YMV6, A5D791, B2GUY1, C0SUT9, F4ICB6, F4JAA5, F4JBP3, O00311, O13889, O22042, P50526, Q0D598, Q0P4S5, Q16659, Q53WJ1, Q5F3W3, Q5R7U1, Q60DG4, Q63185, Q64702, Q6BDA0, Q6DDU8, Q6EU49, Q6L5D4, Q6NPP4, Q6YY75, Q6ZEZ5, Q7T0B0, Q7XIT1, Q8BI55, Q8GSA7, Q8GUI6, Q8L4H0, Q8L840, Q8RXY0, Q93VJ2, Q94C95, Q94CU5, Q9D9X6, Q9FT70

Diamond homologs: A0A194WDG1, A0A509AFG4, A2QU77, A2Y4B6, A4K2M3, A4K2P5, A4K2Q5, A4K2S1, A4K2T0, A4K2W5, A4K2Y1, A8WVU9, A8X6H4, A9S9Q8, B0Y4X4, B5X564, F4I114, F4JPX3, G4N374, G4NH08, G5ECH7, O00311, O13310, O13352, O23236, O35832, O54833, O64483, P06243, P18266, P18431, P19784, P20427, P21127, P21869, P24788, P29620, P33981, P34112, P34117

SIGNOR signaling

35 interactions.

A	Effect	B	Mechanism
CDC7	up-regulates	MCM2	phosphorylation
CHEK1	up-regulates	CDC7	phosphorylation
CDC7	up-regulates	MCM4	phosphorylation
CDC7	up-regulates	MCM7	phosphorylation
CDC7	unknown	RAD18	phosphorylation
CDC7	down-regulates	ESCO1	phosphorylation
CDC7	up-regulates	PSIP1	phosphorylation
“Benzofuro(3,2-d)pyrimidin-4(3H)-one, 8-chloro-2-((2S)-2-pyrrolidinyl)-”	“down-regulates activity”	CDC7	“chemical inhibition”
CDC7	“up-regulates activity”	TARDBP	phosphorylation
CDC7	“up-regulates activity”	CLSPN	phosphorylation
CDC7	“down-regulates activity”	CDC5L	phosphorylation
CDK1	up-regulates	CDC7	phosphorylation
CyclinB/CDK1	“up-regulates activity”	CDC7	phosphorylation
CyclinA2/CDK2	“up-regulates activity”	CDC7	phosphorylation
CyclinE/CDK2	“up-regulates activity”	CDC7	phosphorylation
CDC7	“up-regulates activity”	DTD1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 70 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of the pre-replicative complex	5	48.0×	1e-05
Activation of ATR in response to replication stress	5	44.2×	1e-05
Mitotic G1 phase and G1/S transition	5	27.1×	9e-05
Cell Cycle, Mitotic	5	7.1×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	79
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1537 predictions. Top by Δscore:

Variant	Effect	Δscore
1:91500949:G:GG	donor_gain	1.0000
1:91507848:T:TA	acceptor_gain	1.0000
1:91507852:A:AG	acceptor_gain	1.0000
1:91507852:A:T	acceptor_loss	1.0000
1:91507853:G:GG	acceptor_gain	1.0000
1:91507853:GGT:G	acceptor_gain	1.0000
1:91507935:AAG:A	donor_loss	1.0000
1:91507936:AGGTA:A	donor_loss	1.0000
1:91507937:GG:G	donor_loss	1.0000
1:91507938:G:GC	donor_loss	1.0000
1:91507939:T:A	donor_loss	1.0000
1:91508395:TGGGT:T	donor_loss	1.0000
1:91508396:GG:G	donor_gain	1.0000
1:91508397:GG:G	donor_gain	1.0000
1:91508397:GGTAG:G	donor_loss	1.0000
1:91508398:G:C	donor_loss	1.0000
1:91508398:G:GG	donor_gain	1.0000
1:91508399:T:G	donor_loss	1.0000
1:91511773:T:TA	acceptor_gain	1.0000
1:91511779:A:AG	acceptor_gain	1.0000
1:91511779:AG:A	acceptor_gain	1.0000
1:91511780:G:GC	acceptor_gain	1.0000
1:91511780:GG:G	acceptor_gain	1.0000
1:91511780:GGA:G	acceptor_gain	1.0000
1:91511780:GGAC:G	acceptor_gain	1.0000
1:91511780:GGACA:G	acceptor_gain	1.0000
1:91511807:A:G	acceptor_gain	1.0000
1:91511919:AAAAA:A	donor_gain	1.0000
1:91511920:AAAA:A	donor_gain	1.0000
1:91511921:AAA:A	donor_gain	1.0000

AlphaMissense

3805 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:91508267:T:C	F69L	1.000
1:91508269:C:A	F69L	1.000
1:91508269:C:G	F69L	1.000
1:91508325:C:A	A88D	1.000
1:91508328:T:C	L89P	1.000
1:91508332:A:C	K90N	1.000
1:91508332:A:T	K90N	1.000
1:91511878:G:C	R176P	1.000
1:91511881:A:C	D177A	1.000
1:91511881:A:T	D177V	1.000
1:91511897:T:A	N182K	1.000
1:91511897:T:G	N182K	1.000
1:91513072:A:C	D196A	1.000
1:91513072:A:T	D196V	1.000
1:91513073:C:A	D196E	1.000
1:91513073:C:G	D196E	1.000
1:91507937:G:C	G67R	0.999
1:91507937:G:T	G67C	0.999
1:91508268:T:G	F69C	0.999
1:91508270:A:C	S70R	0.999
1:91508272:C:A	S70R	0.999
1:91508272:C:G	S70R	0.999
1:91508277:T:A	V72D	0.999
1:91508286:C:A	A75D	0.999
1:91508330:A:C	K90Q	0.999
1:91508330:A:G	K90E	0.999
1:91508331:A:T	K90I	0.999
1:91508376:T:C	L105P	0.999
1:91508385:T:C	L108P	0.999
1:91511611:T:A	V117D	0.999

dbSNP variants (sampled 300 via entrez): RS1000114537 (1:91522883 ACAGT>A), RS1000187232 (1:91523172 A>C), RS1000326672 (1:91520929 T>C), RS1000468310 (1:91509946 A>G), RS1000563132 (1:91510240 A>G), RS1000593704 (1:91521196 A>G), RS1000616845 (1:91502815 A>C), RS1000655904 (1:91520700 A>G), RS1000973213 (1:91508761 A>G), RS1001028558 (1:91503071 G>C), RS1001044228 (1:91515404 G>C,T), RS1001062849 (1:91522484 T>C), RS1001284914 (1:91501043 T>C,G), RS1001616540 (1:91522323 G>T), RS1002069745 (1:91502443 CTG>C)

Disease associations

OMIM: gene MIM:603311 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): premature menopause (MONDO:0001119)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

24 associations (top):

Study	Trait	p-value
GCST000699_3	Optic disc parameters	3.000000e-28
GCST000970_3	Optic disc area	8.000000e-17
GCST002626_1	Vertical cup-disc ratio	1.000000e-15
GCST002765_1	Optic disc area	8.000000e-56
GCST002765_6	Optic disc area	4.000000e-38
GCST003485_4	Response to fenofibrate (HDL cholesterol levels)	3.000000e-06
GCST004047_1	Optic nerve measurement (cup-to-disc ratio)	1.000000e-07
GCST004075_26	Vertical cup-disc ratio	3.000000e-20
GCST004075_27	Vertical cup-disc ratio	2.000000e-23
GCST004076_16	Optic disc area	6.000000e-81
GCST004076_2	Optic disc area	2.000000e-60
GCST004185_5	Lung function (FEV1/FVC)	6.000000e-20
GCST004600_63	Eosinophil percentage of white cells	7.000000e-09
GCST004899_6	Gestational age at birth (maternal effect)	9.000000e-07
GCST008391_1	Glaucoma (primary open-angle)	2.000000e-08
GCST008482_1	Lung function (FVC)	8.000000e-07
GCST009411_10	Optic disc area	4.000000e-64
GCST009412_8	Vertical cup-disc ratio	1.000000e-18
GCST009462_20	Optic disc size	3.000000e-160
GCST009724_86	Vertical cup-disc ratio (multi-trait analysis)	7.000000e-51
GCST010320_94	PR interval	3.000000e-09
GCST010321_176	PR interval	2.000000e-08
GCST90002400_38	Plateletcrit	1.000000e-10
GCST90011770_30	Glaucoma (primary open-angle)	1.000000e-29

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0007805	HDL cholesterol change measurement
EFO:0006939	cup-to-disc ratio measurement
EFO:0004713	FEV/FVC ratio
EFO:0007991	eosinophil percentage of leukocytes
EFO:0005112	gestational age
EFO:0005939	parental genotype effect measurement
EFO:0004312	vital capacity
EFO:0004462	PR interval
EFO:0007985	platelet crit

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008594	Menopause, Premature	C12.050.351.500.056.630.250; C12.100.250.056.630.250; G08.686.157.500.500; G08.686.841.249.500.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2111377 (PROTEIN COMPLEX), CHEMBL4523630 (PROTEIN COMPLEX), CHEMBL5443 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

7 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 4,762 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4297644	SIMUROSERTIB	2	63
CHEMBL1232461	MOLIBRESIB	2	1,538
CHEMBL1967878	CENISERTIB	2	358
CHEMBL475251	R-406	2	762
CHEMBL4868568	MONZOSERTIB	2	14
CHEMBL495727	AT-9283	2	1,376
CHEMBL482967	CYC-116	1	651

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CDC7 family

Most potent curated ligand interactions (8 total), top 8:

Ligand	Action	Affinity	Parameter
compound 2 [PMID: 22560567]	Inhibition	8.85	pIC50
compound 89S [PMID: 19115845]	Inhibition	8.7	pIC50
monzosertib	Inhibition	8.62	pIC50
XL413	Inhibition	8.47	pIC50
compound 74 [PMID: 24793884]	Inhibition	8.42	pIC50
compound 77 [PMID: 24793884]	Inhibition	8.17	pIC50
compound 18 [PMID: 20873740]	Inhibition	7.66	pIC50
compound 1 [PMID: 24793884]	Inhibition	6.49	pIC50

Binding affinities (BindingDB)

187 measured of 340 human assays (340 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
5-[1-benzyl-5-[4-(dimethylamino)phenyl]triazol-4-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	0.4 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
N-[5-(1-benzyltriazol-4-yl)-1H-indazol-3-yl]benzamide	KI	0.4 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-[1-benzyl-5-(4-fluorophenyl)triazol-4-yl]-3-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazole	KI	0.428 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
N-[5-(1-benzyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]-3-fluorobenzamide	KI	0.5 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-(1-benzyl-5-thiophen-2-yltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	0.5 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
8-methyl-11-thia-9,14,16-triazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1,7,9,12(17),13,15-hexaen-13-amine	KI	0.5 nM
5-(1-benzyl-5-phenyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazole	KI	0.601 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-[1-benzyl-5-(4-fluorophenyl)triazol-4-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	0.8 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
N-[5-(1-benzyl-5-phenyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]benzamide	KI	0.8 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
N-[5-(1-benzyl-5-cyclopropyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-yl]-3-fluorobenzamide	KI	0.9 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
(2Z)-5-(1H-indazol-5-ylimino)-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolan-3-one	IC50	1 nM	US-8742113: Furanone derivative
(2Z)-5-[(3-methylthiophen-2-yl)methylimino]-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolan-3-one	IC50	1 nM	US-8742113: Furanone derivative
12-ethyl-11,13-dimethyl-8-thia-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2(7),3,5,9,11-hexaen-6-amine	KI	1 nM
5-[5-(4-fluorophenyl)-1-(oxan-4-ylmethyl)triazol-4-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazole	KI	1.05 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-(1,5-dibenzyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	1.1 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-(1-benzyl-5-phenyltriazol-4-yl)-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	1.2 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
5-[1-benzyl-5-(1-methylpyrazol-4-yl)triazol-4-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	1.9 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
ethyl (5Z)-2-(2-chlorophenyl)imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	2 nM	US-8742113: Furanone derivative
(2Z)-5-(4-fluoro-2-methylphenyl)imino-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolan-3-one	IC50	2 nM	US-8742113: Furanone derivative
7-ethyl-2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	2 nM
7-(2-fluoroethyl)-2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	2 nM
2-(2-aminopyrimidin-4-yl)-7,7-dimethyl-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	2 nM
(7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	2 nM
5,13,17-triazatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2(7),3,5,8,11(16)-hexaen-12-one	IC50	2 nM
9-methyl-17-thia-2,12,14-triazatetracyclo[8.7.0.0^{3,8}.0^{11,16}]heptadeca-1,3(8),9,11(16),12,14-hexaen-15-amine	KI	2 nM
11,13-dimethyl-12-(prop-2-en-1-yl)-8-thia-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2(7),3,5,9,11-hexaen-6-amine	KI	2 nM
5-[1-benzyl-5-(2-methylphenyl)triazol-4-yl]-3-methyl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazole	KI	2.25 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
3-hydroxypropyl (5Z)-2-(4-fluorophenyl)imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	3 nM	US-8742113: Furanone derivative
ethyl (5Z)-2-[4-(2-hydroxyethylamino)-2-methylphenyl]imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	3 nM	US-8742113: Furanone derivative
ethyl (2Z,5Z)-2-morpholin-4-ylimino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	3 nM	US-8742113: Furanone derivative
propan-2-yl (5Z)-2-[4-(2-hydroxyethoxy)-2-methylphenyl]imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	3 nM	US-8742113: Furanone derivative
2-methoxyethyl (5Z)-2-(2-chlorophenyl)imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	3 nM	US-8742113: Furanone derivative
6-(2-methylpropyl)-2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	3 nM
7-cyclobutyl-2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	3 nM
7,7-dimethyl-2-(pyridin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	3 nM
2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	3 nM
2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	3 nM
7-methyl-10-thia-8,13,15-triazatetracyclo[7.7.0.0^{2,6}.0^{11,16}]hexadeca-1,6,8,11(16),12,14-hexaen-12-amine	KI	3 nM
5-[1-benzyl-5-(2-methylphenyl)triazol-4-yl]-2,3,3a,4,5,6,7,7a-octahydro-1H-indazol-3-amine	KI	3.4 nM	US-9163007: 5-substituted indazoles as kinase inhibitors
ethyl (5Z)-2-(1H-indazol-6-ylimino)-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	4 nM	US-8742113: Furanone derivative
2-(dimethylamino)ethyl (5Z)-2-(2,4-difluorophenyl)imino-4-oxo-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolane-3-carboxylate	IC50	4 nM	US-8742113: Furanone derivative
US8742113, 102	IC50	4 nM	US-8742113: Furanone derivative
(2Z)-5-cycloheptylimino-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylidene)oxolan-3-one	IC50	4 nM	US-8742113: Furanone derivative
US8742113, 244	IC50	4 nM	US-8742113: Furanone derivative
2-(2-aminopyrimidin-4-yl)-7-(propan-2-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	4 nM
2-(2-aminopyrimidin-4-yl)-7-(2-hydroxyethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	4 nM
2-(2-amino-5-bromopyrimidin-4-yl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	4 nM
2-(2-aminopyrimidin-4-yl)-1-(cyclopropylmethyl)-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-4-one	IC50	4 nM
11,12,13-trimethyl-8-thia-3,5,10-triazatricyclo[7.4.0.0^{2,7}]trideca-1(13),2(7),3,5,9,11-hexaen-6-amine	KI	4 nM
5-(1-benzyltriazol-4-yl)-3-thiophen-2-yl-2,3,3a,4,5,6,7,7a-octahydro-1H-indazole	KI	4.92 nM	US-9163007: 5-substituted indazoles as kinase inhibitors

ChEMBL bioactivities

1040 potent at pChembl≥5 of 1063 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.05	Ki	0.09	nM	CHEMBL1958411
9.96	Ki	0.11	nM	CHEMBL1958417
9.92	Ki	0.12	nM	CHEMBL1958412
9.90	Ki	0.1259	nM	CHEMBL244793
9.90	Ki	0.1259	nM	CHEMBL1964519
9.85	Ki	0.14	nM	CHEMBL1958416
9.80	Ki	0.1585	nM	CHEMBL2062936
9.80	IC50	0.16	nM	CHEMBL4436649
9.80	IC50	0.16	nM	CHEMBL4462898
9.80	Ki	0.1585	nM	CHEMBL1986943
9.80	Ki	0.1585	nM	CHEMBL2005509
9.74	Ki	0.18	nM	CHEMBL1958414
9.74	Ki	0.18	nM	CHEMBL1958415
9.70	Ki	0.2	nM	CHEMBL1958419
9.70	Ki	0.2	nM	CHEMBL1958420
9.70	Ki	0.1995	nM	CHEMBL1965660
9.70	Ki	0.1995	nM	CHEMBL1992220
9.60	Ki	0.25	nM	CHEMBL1958418
9.60	Ki	0.2512	nM	CHEMBL1980562
9.59	IC50	0.26	nM	SIMUROSERTIB
9.55	Ki	0.28	nM	CHEMBL1958408
9.52	Ki	0.3	nM	CHEMBL1958406
9.50	Ki	0.3162	nM	CHEMBL2062937
9.50	Ki	0.3162	nM	CHEMBL1980253
9.50	Ki	0.3162	nM	CHEMBL1996980
9.50	Ki	0.3162	nM	CHEMBL1969151
9.50	Ki	0.3162	nM	CHEMBL1973720
9.50	Ki	0.3162	nM	CHEMBL1992363
9.50	Ki	0.3162	nM	CHEMBL1982271
9.40	Ki	0.4	nM	CHEMBL1969221
9.40	Ki	0.4	nM	CHEMBL1999931
9.40	Ki	0.3981	nM	CHEMBL1981079
9.40	Ki	0.3981	nM	CHEMBL1972339
9.40	Ki	0.3981	nM	CHEMBL1969221
9.40	Ki	0.3981	nM	CHEMBL2002613
9.40	Ki	0.3981	nM	CHEMBL1979933
9.40	Ki	0.3981	nM	CHEMBL2005216
9.39	IC50	0.41	nM	CHEMBL4439133
9.37	Ki	0.428	nM	CHEMBL1972339
9.37	Kd	0.424	nM	SIMUROSERTIB
9.37	IC50	0.43	nM	CHEMBL4570191
9.36	IC50	0.44	nM	CHEMBL4439133
9.36	IC50	0.44	nM	CHEMBL4471906
9.30	Ki	0.5012	nM	CHEMBL1999931
9.30	Ki	0.5	nM	CHEMBL2003638
9.30	Ki	0.5	nM	CHEMBL3890525
9.30	Ki	0.5	nM	CHEMBL505372
9.30	Ki	0.5	nM	CHEMBL1958404
9.30	Ki	0.5	nM	CHEMBL1958408
9.30	Ki	0.5012	nM	CHEMBL2006450

PubChem BioAssay actives

758 with measured affinity, of 1861 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(cyclohexylamino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-(benzylamino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-anilino-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-(oxan-4-ylamino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-[cyclohexyl(methyl)amino]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-[(1-methylpiperidin-4-yl)amino]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0001	uM
2-(4-hydroxypiperidin-1-yl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0002	uM
2-[bis(2-methoxyethyl)amino]-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0002	uM
2-morpholin-4-yl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0002	uM
2-(4-methoxypiperidin-1-yl)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0002	uM
2-(7-azabicyclo[2.2.1]heptan-1-yl)-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one;hydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0002	uM
2-(2-azabicyclo[2.1.1]hexan-1-yl)-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0002	uM
4-[[4-chloro-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]cyclohexan-1-ol	673702: Inhibition of CDC7	ki	0.0002	uM
2-[(2S)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0003	uM
2-phenyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0003	uM
4-(cyclohexylamino)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-1,3,5-triazin-2-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0003	uM
1-N-[4-chloro-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]-4-N,4-N-dimethylcyclohexane-1,4-diamine	673702: Inhibition of CDC7	ki	0.0003	uM
6-(cyclohexylamino)-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyridin-2-one	727789: Inhibition of human Cdc7 using biotin-C6linker-TPSDSLIYDDGLS as substrate after 1 hr	ki	0.0003	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2S)-piperidin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0004	uM
2-[(2S)-piperidin-2-yl]-6-[5-(trifluoromethyl)-1H-pyrazol-4-yl]-3H-thieno[3,2-d]pyrimidin-4-one;hydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0004	uM
8-methyl-11-thia-9,14,16-triazatetracyclo[8.7.0.02,7.012,17]heptadeca-1,7,9,12,14,16-hexaen-13-amine	1798805: Radioactive Kinase Assay from Article 10.1016/j.bmcl.2008.11.093: “Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.”	ki	0.0005	uM
2-(cyclohexylamino)-4-(1H-indazol-5-yl)-1H-pyrimidin-6-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0005	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-(pyrrolidin-1-ylmethyl)-3H-thieno[3,2-d]pyrimidin-4-one	1453928: Binding affinity to recombinant human full length Cdc7 (1 to 574 residues)/human N-terminal GST-tagged ASK (1 to 674 residues) expressed in baculovirus expression system by proteros reporter displacement assay	kd	0.0005	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2S)-1,2,3,6-tetrahydropyridin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0005	uM
N-[5-(1-benzyltriazol-4-yl)-1H-indazol-3-yl]benzamide	673702: Inhibition of CDC7	ki	0.0005	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2S,3S)-3-methylpyrrolidin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0006	uM
methyl 2-(2-chloroanilino)-4-hydroxy-5-[(Z)-pyrrolo[2,3-b]pyridin-3-ylidenemethyl]furan-3-carboxylate	1444134: Inhibition of recombinant human Cdc7 (1 to 574 residues)/human N-terminal GST-tagged ASK (1 to 674 residues) expressed in baculovirus expression system using FITC-labeled MCM2 peptide as substrate measured after 5 hrs in presence of 5 uM ATP	ic50	0.0006	uM
N-[(R)-cyclopropyl-(2-fluoro-3-pyridinyl)methyl]-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine	1056819: Inhibition of Cdc7/Dbf4 (unknown origin)-mediated MCM2 phosphorylation at Ser53 by protein A amplified luminescent proximity homogeneous assay	ic50	0.0007	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2S)-pyrrolidin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0007	uM
N-[(R)-cyclopropyl-(2-fluorophenyl)methyl]-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine	1056819: Inhibition of Cdc7/Dbf4 (unknown origin)-mediated MCM2 phosphorylation at Ser53 by protein A amplified luminescent proximity homogeneous assay	ic50	0.0008	uM
N-[5-(1-benzyltriazol-4-yl)-1H-indazol-3-yl]-3-chlorobenzamide	673702: Inhibition of CDC7	ki	0.0008	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2R)-piperidin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0009	uM
6-chloro-N-cyclohexyl-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2-amine	727789: Inhibition of human Cdc7 using biotin-C6linker-TPSDSLIYDDGLS as substrate after 1 hr	ki	0.0009	uM
2-(2-aminopyrimidin-4-yl)-7-propan-2-yl-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one	411539: Inhibition of human Cdc7 assessed as inhibition of rate of phosphorylation of Mcm2 protein	ic50	0.0010	uM
N-[(R)-cyclopropyl(phenyl)methyl]-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine	1056819: Inhibition of Cdc7/Dbf4 (unknown origin)-mediated MCM2 phosphorylation at Ser53 by protein A amplified luminescent proximity homogeneous assay	ic50	0.0010	uM
2-[(2R)-1-azabicyclo[2.2.2]octan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0010	uM
12-ethyl-11,13-dimethyl-8-thia-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-6-amine	1798805: Radioactive Kinase Assay from Article 10.1016/j.bmcl.2008.11.093: “Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.”	ki	0.0010	uM
1,2-dimethyl-6-(5-methyl-1H-pyrazol-4-yl)-2-(2,2,2-trifluoroethyl)-3H-thieno[3,2-d]pyrimidin-4-one	1364441: Inhibition of recombinant human Cdc7 (1 to 574 residues)/human N-terminal GST-tagged DBF4 (1 to 674 residues) expressed in baculovirus expression system using His-tagged MCM2 as substrate preincubated for 10 mins followed by ATP addition by HTRF assay	ic50	0.0010	uM
2-pyridin-4-ylspiro[5,6-dihydrothieno[3,2-c]pyridine-7,1’-cyclohexane]-4-one	656449: Inhibition of CDC7/DBF4 using MCM-2 as substrate after 1 hr	ic50	0.0010	uM
2-(1H-pyrazol-4-yl)spiro[5,6-dihydrothieno[3,2-c]pyridine-7,1’-cyclohexane]-4-one	656449: Inhibition of CDC7/DBF4 using MCM-2 as substrate after 1 hr	ic50	0.0010	uM
2-(1H-pyrazol-4-yl)spiro[5,6-dihydro-1-benzothiophene-7,1’-cyclohexane]-4-one	656449: Inhibition of CDC7/DBF4 using MCM-2 as substrate after 1 hr	ic50	0.0010	uM
2-(7H-purin-6-yl)spiro[5,6-dihydrothieno[3,2-c]pyridine-7,1’-cyclohexane]-4-one	656449: Inhibition of CDC7/DBF4 using MCM-2 as substrate after 1 hr	ic50	0.0010	uM
N-[(R)-cyclopropyl-(2-fluoro-3-pyridinyl)methyl]-5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-1,3,4-oxadiazol-2-amine	1056819: Inhibition of Cdc7/Dbf4 (unknown origin)-mediated MCM2 phosphorylation at Ser53 by protein A amplified luminescent proximity homogeneous assay	ic50	0.0011	uM
2-[[(3S)-3-fluoropyrrolidin-1-yl]methyl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one	1453917: Inhibition of recombinant human full length Cdc7 (1 to 574 residues)/human N-terminal GST-tagged ASK (1 to 674 residues) expressed in baculovirus expression system using N-terminal His-tagged MCM2 as substrate pretreated for 10 mins followed by ATP addition by TR-FRET assay	ic50	0.0011	uM
4-(cyclohexylamino)-6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-1H-pyridin-2-one	651006: Inhibition of human CDC7/DBF4 expressed using baculovirus expression system assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	ki	0.0011	uM
2-[(2S)-azepan-2-yl]-6-(5-methyl-1H-pyrazol-4-yl)-3H-thieno[3,2-d]pyrimidin-4-one	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0012	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[[(2S)-2-methylpyrrolidin-1-yl]methyl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1453917: Inhibition of recombinant human full length Cdc7 (1 to 574 residues)/human N-terminal GST-tagged ASK (1 to 674 residues) expressed in baculovirus expression system using N-terminal His-tagged MCM2 as substrate pretreated for 10 mins followed by ATP addition by TR-FRET assay	ic50	0.0012	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148040: Binding affinity to human CDC7 incubated for 45 mins by Kinobead based pull down assay	kd	0.0012	uM
1’-(4-fluorophenyl)-1’-hydroxy-6-(5-methyl-1H-pyrazol-4-yl)spiro[1,3-dihydrothieno[3,2-d]pyrimidine-2,4’-cyclohexane]-4-one	1364441: Inhibition of recombinant human Cdc7 (1 to 574 residues)/human N-terminal GST-tagged DBF4 (1 to 674 residues) expressed in baculovirus expression system using His-tagged MCM2 as substrate preincubated for 10 mins followed by ATP addition by HTRF assay	ic50	0.0012	uM
6-(5-methyl-1H-pyrazol-4-yl)-2-[(2S,4S)-4-methylpyrrolidin-2-yl]-3H-thieno[3,2-d]pyrimidin-4-one;dihydrochloride	1528722: Inhibition of N-terminal GST-fused full-length human CDC7 (1 to 574 end residues)/DBF4 (1 to 674 residues) expressed in baculovirus expression system using MCM2 as substrate preincubated with enzyme for 10 mins prior to 1 uM ATP addition by HTRF transcreener ADP assay	ic50	0.0013	uM

CTD chemical–gene interactions

71 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, increases expression, affects expression	4
Cyclosporine	decreases expression	4
trichostatin A	affects cotreatment, decreases expression, affects expression	3
Benzo(a)pyrene	increases expression, affects methylation	3
Tetrachlorodibenzodioxin	affects expression, decreases expression	3
lasiocarpine	decreases expression, increases metabolic processing, increases expression	2
sodium arsenite	affects methylation, decreases expression	2
Carbamazepine	affects expression	2
Copper	increases expression, decreases expression, affects binding	2
Doxorubicin	affects response to substance, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Quercetin	decreases expression, affects expression	2
Tobacco Smoke Pollution	decreases expression	2
Tretinoin	decreases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
Cadmium Chloride	decreases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
afuresertib	decreases expression	1
FR900359	decreases phosphorylation	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
geraniol	decreases expression	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
ochratoxin A	decreases expression, affects cotreatment	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
beta-methylcholine	affects expression	1
celastrol	decreases expression	1

ChEMBL screening assays

222 unique, capped per target: 221 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1035818	Binding	Inhibition of human recombinant Cdc7/Dbf4 by IMAP assay	Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors. — Bioorg Med Chem Lett
CHEMBL1963731	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CDC7	PubChem BioAssay data set

Clinical trials (associated diseases)

82 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists